Arca
Skip to content
Tools
Tools

Systemic lupus erythematosus

Drug research and approvals for systemic lupus erythematosus: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 288 studies of systemic lupus erythematosus are recruiting on ClinicalTrials.gov, Health Canada has authorized 29 drug trials for it since 2013, FDA has 0 approved and 3 open orphan designations naming it, and the EU has 2 authorised medicines for it.

  • Recruiting worldwide: 288
  • Trials authorized in Canada: 29
  • FDA orphan approvals: 0
  • EU medicines: 2

Recruiting now

Newest posted first, of 288 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 5

Phase 3 12 of 28

Phase 2 12 of 66

Phase 1 or earlier 12 of 32

How its trials ended

967 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 228 whose ending is known, 39% met their primary endpoint, 11% missed it and 50% stopped early.

  • Completed, result not reported31633%
  • Ongoing28930%
  • Status unknown13414%
  • Met its primary endpoint909%
  • Stopped: other or unclear586%
  • Missed its primary endpoint242%
  • Stopped: enrollment or feasibility232%
  • Stopped: sponsor or business decision172%
  • Stopped: lack of efficacy121%
  • Stopped: safety2<1%
  • Stopped: funding2<1%

Trials authorized in Canada

The 10 newest of 29; search them all in Canada trials
Jan 20, 2026Multinational, interventional, 52-week, open-label, single-arm study to evaluate the treatment outcomes of anifrolumab 120 mg subcutaneous once weekly in…Anifrolumab (MEDI-546)AstraZeneca PharmaceuticalsOngoing
Dec 23, 2025Phase 1b/2 study of AZD0120, a chimeric antigen receptor T-cell (car t) therapy targeting CD19 and B-cell maturation antigen (BCMA) in subjects with refractory…AZD0120 (GC012F)AstraZeneca PharmaceuticalsPending
Aug 1, 2025A phase 2, multicenter, open-label study of CC-97540 (BMS-986353), CD19-targeted nex-t car t cells, in participants with active SLE (including lupus nephritis)…BMS-986353 (CC-97540)Bristol-Myers SquibbOngoing
Dec 17, 2024A phase 2, adaptive, randomized, open-label, assessor-blinded active-controlled study to evaluate the efficacy and safety of rapcabtagene autoleucel versus…YTB323 (rapcabtagene autoleucel) / Fludarabine phosphate / CyclophosphamideNovartis PharmaceuticalsPending
Nov 14, 2024A phase I study to evaluate the safety and preliminary efficacy of ATA3219, allogeneic anti CD19 chimeric antigen receptor t cell (car t) therapy, in subjects…ATA3219 / Fludarabine phosphate / Cyclophosphamide / Methylprednisolone sodium…Atara BiotherapeuticsPending
Sep 13, 2024A phase 1 study to evaluate the efficacy and safety of AB-101, an allogeneic cord blood derived nk-cell therapy in combination with B-cell depleting mab in…AB-101 / Truxima (rituximab) / Gazyvaro (obinutuzumab)Artiva BiotherapeuticsPending
Feb 12, 2024A randomized, double-blind, placebo-controlled extension study to assess the long-term safety and tolerability of ianalumab in patients with systemic lupus…Ianalumab (VAY736)Novartis PharmaceuticalsOngoing
Oct 25, 2023A phase 2a, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of MK-6194 in adult participants with systemic…MK-6194Merck & Co. (MSD)Ongoing
Jun 29, 2023A phase III, randomized, double-blind, parallel-group, placebo controlled study to evaluate the pharmacokinetics, pharmacodynamics, efficacy, and safety of iv…SaphneloAstraZeneca PharmaceuticalsOngoing
Feb 9, 2023A phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of deucravacitinib in participants with active systemic lupus…Deucravacitinib (BMS-986165)Bristol-Myers SquibbOngoing

FDA orphan designations

Approved first, then open designations, newest first
Feb 9, 1999Humanized MAb (IDEC-131) to CD40LTreatment of systemic lupus erythematosus.Biogen IdecInc.Designated
Feb 18, 1998Recombinant humanized monoclonal antibody 5c8Treatment of systemic lupus erythematosus.Biogen, Inc.Designated
Jul 13, 1994DehydroepiandrosteroneTreatment of systemic lupus erythematosus (SLE) and the reduction in the use of steroids in steroid-dependent SLE patients.GlaxoSmithKlineDesignated

Medicines authorised in the EU

Newest first
Feb 14, 2022SaphneloAnifrolumabAstraZeneca ABEMA ↗
Jul 13, 2011BenlystaBelimumabGlaxoSmithKline (Ireland) LimitedEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.